HLA最新文献 - Book学术

Discovery of the Novel HLA-DQB1*06:552 Allele in a Taiwanese Individual. 台湾人HLA-DQB1*06:552等位基因的发现

IF 4.1 4区医学

HLA Pub Date : 2026-05-01 DOI: 10.1111/tan.70744

Kuo-Liang Yang, Py-Yu Lin

引用次数: 0

Extended Characterisation of the Coding Sequence of the HLA-A*11:124 Allele by Next- and Third-Generation Sequencing. HLA-A* 11:24等位基因编码序列的第二代和第三代测序扩展表征。

IF 4.1 4区医学

HLA Pub Date : 2026-05-01 DOI: 10.1111/tan.70741

Romain Ferru-Clément, Yannick Branger, Clara Levée, Isabelle Jollet

引用次数: 0

Comparison of Labscan 200 and FlexMap 3D Luminex for Anti-HLA Antibodies Monitoring. Labscan 200与FlexMap 3D Luminex用于hla抗体监测的比较

IF 4.1 4区医学

HLA Pub Date : 2026-05-01 DOI: 10.1111/tan.70731

J Milhès, L Duclercq, S Blavy, A Del Bello, N Kamar, C Bouthemy, N Congy-Jolivet

{"title":"Comparison of Labscan 200 and FlexMap 3D Luminex for Anti-HLA Antibodies Monitoring.","authors":"J Milhès, L Duclercq, S Blavy, A Del Bello, N Kamar, C Bouthemy, N Congy-Jolivet","doi":"10.1111/tan.70731","DOIUrl":"https://doi.org/10.1111/tan.70731","url":null,"abstract":"The new Luminex model FlexMap 3D is progressively replacing the previous Luminex generation in HLA laboratories for the detection and identification of anti-HLA antibodies. FlexMap 3D Luminex promises a higher degree of sensitivity, which may lead to greater mean fluorescence intensities, depending on the anti-HLA beads kit supplier. Given that anti-HLA antibodies and potential donor specific antibodies monitoring rely on MFI variations, all kits routinely used and especially Single Antigen Beads assays must be compared. In the HLA Laboratory at Toulouse Hospital, we compared the two Luminex generations using LABScreen Mix, Panel Reactive Antibody and LABScreen Single Antigen from One Lambda and Lifecodes ID from Werfen suppliers. LABScreen Mix, Panel Reactive Antibodies and Single Antigen gave the same results with both Luminex platforms. It should be noted that a divider was applied to all results obtained with FlexMap 3D when using One Lambda kits, which enabled us to obtain comparable MFI. Lifecodes ID also showed a strong correlation with both Luminex instruments, but no divider was applied and higher MFI were attained on FlexMap 3D. Serial dilutions of two monoclonal antibodies also illustrated that MFI achieved with Single Antigen from Werfen on FlexMap 3D Luminex were closer to One Lambda values. All MFI obtained with One Lambda were virtually identical when using Labscan 200 or FlexMap 3D, allowing the switch to the new Luminex platform to be made without issue. MFI gained with Werfen was higher with FlexMap 3D Luminex, which increases sensitivity, and may facilitate MFI comparisons between the two suppliers.","PeriodicalId":13172,"journal":{"name":"HLA","volume":"107 5","pages":"e70731"},"PeriodicalIF":4.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13144444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Blockade of Complement Cell Lysis and C3d Fixation by Patient HLA-A1 Antibodies: Towards a New Therapy for Prevention of Antibody-Mediated Rejection. 患者HLA-A1抗体阻断补体细胞溶解和C3d固定：一种预防抗体介导的排斥反应的新疗法

IF 4.1 4区医学

HLA Pub Date : 2026-05-01 DOI: 10.1111/tan.70745

Tineke Kardol-Hoefnagel, Dilara Akharman-Oztoprak, Els van der Meijden, Frans H Claas, Frank J Beurskens, Henny G Otten

{"title":"Blockade of Complement Cell Lysis and C3d Fixation by Patient HLA-A1 Antibodies: Towards a New Therapy for Prevention of Antibody-Mediated Rejection.","authors":"Tineke Kardol-Hoefnagel, Dilara Akharman-Oztoprak, Els van der Meijden, Frans H Claas, Frank J Beurskens, Henny G Otten","doi":"10.1111/tan.70745","DOIUrl":"https://doi.org/10.1111/tan.70745","url":null,"abstract":"Donor-specific HLA antibodies (DSA) occurring prior to or appearing de novo after transplantation play a major role in kidney graft loss, mainly caused by complement activation by DSA. As potential therapeutics, immunologically inert human monoclonal antibodies (mAbs) preventing binding of DSA to HLA-A1 molecules would limit their detrimental effects. In this study, the complement-activating potential of anti-HLA-A1 mAbs (WIM8E5), modified by single amino-acid changes inhibiting C1q binding, Fc-Fc interactions, or FcγR binding, was assessed in the classical crossmatch and by detection of C3d fixation in single antigen Luminex beads. Subsequently, the efficacy of these modified human mAbs was assessed in combination with patient sera to determine whether they could prevent complement-mediated cell lysis and HLA antibodies-induced C3d fixation. Point mutations in anti-HLA-A1-WIM8E5 mAb preventing C1q binding resulted in reduced to absent complement-mediated cell lysis and C3d fixation. Patient sera containing anti-HLA-A1 antibodies are able to activate complement, and WIM8E5-K322A-P329R-S440K (preventing C1q, Fc:Fc interaction and FcyR binding) mAb could prevent cell lysis induced by patient antibodies and inhibit C3d binding to HLA-A1 coated beads. Furthermore, the 109F epitope recognized by the mAb differed from those recognized by patient antibodies, indicating that a single modified mAb can block multiple HLA-A1 recognition sites. In conclusion, single amino-acid mutations in anti-HLA-A1-WIM8E5 directed to inhibit C1q binding, Fc:Fc interactions, or FcγR binding could be used to prevent complement-mediated cell lysis and C3d formation in kidney transplant recipients. Further research is needed to investigate the applicability of modified mAb as potential therapeutics in the clinic.","PeriodicalId":13172,"journal":{"name":"HLA","volume":"107 5","pages":"e70745"},"PeriodicalIF":4.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13147309/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identification of the Full Genomic Sequence of the HLA-DRB1*13:370N Allele by Next Generation Sequencing. HLA-DRB1*13:370N等位基因全基因组序列的下一代测序鉴定

IF 4.1 4区医学

HLA Pub Date : 2026-05-01 DOI: 10.1111/tan.70747

Myriam Dollerschell, Cécilia Da Costa, Judith Desoutter, Julien Lion, Nicolas Guillaume

引用次数: 0

Identification of the Novel MICA*292 Allele in a Chinese Cord Blood Donor. 中国脐带血献血者MICA*292等位基因的鉴定

IF 4.1 4区医学

HLA Pub Date : 2026-05-01 DOI: 10.1111/tan.70738

Lina Dong, Yizhen He, Nanying Chen, Wei Zhang, Faming Zhu

引用次数: 0

Genomic Confirmation of HLA-C*12:68 by Next Generation Sequencing. HLA-C*12:68的下一代测序证实。